Maprotiline (Ludiomil, Ciba 34,276-BA) and imipramine in depressed outpatients: a double-blind clinical study.
D000328:Adult; D000553:Ambulatory Care; D000704:Analysis of Variance; D000873:Anthracenes / Q000627:therapeutic use*; D000928:Antidepressive Agents / Q000627:therapeutic use*; D001007:Anxiety / Q000188:drug therapy; D002986:Clinical Trials as Topic; D003863:Depression / Q000188:drug therapy*; D004341:Drug Evaluation; D004569:Electroencephalography; D005260:Female; D006791:Hostility / Q000187:drug effects; D006801:Humans; D007099:Imipramine / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008376:Maprotiline / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D011602:Psychophysiologic Disorders / Q000188:drug therapy; D012893:Sleep Wake Disorders / Q000188:drug therapy
D000873:Anthracenes; D000928:Antidepressive Agents; D008376:Maprotiline; D007099:Imipramine